Red Arrow Therapeutics, Inc. is a biotechnology company focusing on developing new technologies that can turn "cold" tumors into inflamed "hot" tumors. Red Arrow Therapeutics' lead product candidate, RA-001, a pH-activated polymer micelle loaded with IL-12, is designed to release fully active IL-12 upon sensing intratumoral pH to safely potentiate immunotherapy.
In the current pre-clinical data, RA-001 exhibits strong anti-tumor immunity in various tumor models. Furthermore, RA-001 shows high efficacy as monotherapy and in combination with immune checkpoint inhibitors.